Yi Zhou1, Qiao Yang2, Jun Ye3, Xiaocheng Wu4, Xianhua Hou5, Yimei Feng6, Bangyu Luo1, Jixi Li1, Guangrong Yang1, Lingchen Li1, Xiu Yang1, Bin Wang7, Songtao Zhao8, Li Li9, Qi Li10, Zhi Xu11, Hao Wu12, Jianguo Sun13. 1. Cancer Institute, Xinqiao Hospital, Army Medical University, 83 Xinqiao Zhengjie Road, Shapingba, Chongqing, 400037, People's Republic of China. 2. Department of Ultrasound, The 941st Hospital of the PLA Joint Logistic Support Force, Xining, People's Republic of China. 3. Department of Gastroenterology, Southwest Hospital, Army Medical University, Chongqing, People's Republic of China. 4. Department of Emergency, Xinqiao Hospital, Army Medical University, Chongqing, People's Republic of China. 5. Department of Neurology, Southwest Hospital, Army Medical University, Chongqing, People's Republic of China. 6. Department of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, People's Republic of China. 7. Department of Respiratory and Intensive Care, Xinqiao Hospital, Army Medical University, 83 Xinqiao Zhengjie Road, Shapingba, Chongqing, 400037, People's Republic of China. 8. Institute of Infectious Diseases, Southwest Hospital, Army Medical University, Chongqing, People's Republic of China. 9. Department of Respiratory Medicine, Army Medical Center, Chongqing, People's Republic of China. 10. Department of Respiratory and Intensive Care, Xinqiao Hospital, Army Medical University, 83 Xinqiao Zhengjie Road, Shapingba, Chongqing, 400037, People's Republic of China. liqioliver@sina.com. 11. Department of Respiratory and Intensive Care, Xinqiao Hospital, Army Medical University, 83 Xinqiao Zhengjie Road, Shapingba, Chongqing, 400037, People's Republic of China. xu_zhi999@163.com. 12. Xinqiao Hospital, Army Medical University, 83 Xinqiao Zhengjie Road, Shapingba, Chongqing, 400037, People's Republic of China. ewuhao@163.com. 13. Cancer Institute, Xinqiao Hospital, Army Medical University, 83 Xinqiao Zhengjie Road, Shapingba, Chongqing, 400037, People's Republic of China. sunjg09@aliyun.com.
Abstract
BACKGROUND: Coronavirus disease 2019 (COVID-19) has spread around the world. This retrospective study aims to analyze the clinical features of COVID-19 patients with cancer and identify death outcome related risk factors. METHODS: From February 10th to April 15th, 2020, 103 COVID-19 patients with cancer were enrolled. Difference analyses were performed between severe and non-severe patients. A propensity score matching (PSM) analysis was performed, including 103 COVID-19 patients with cancer and 206 matched non-cancer COVID-19 patients. Next, we identified death related risk factors and developed a nomogram for predicting the probability. RESULTS: In 103 COVID-19 patients with cancer, the main cancer categories were breast cancer, lung cancer and bladder cancer. Compared to non-severe patients, severe patients had a higher median age, and a higher proportion of smokers, diabetes, heart disease and dyspnea. In addition, most of the laboratory results between two groups were significantly different. PSM analysis found that the proportion of dyspnea was much higher in COVID-19 patients with cancer. The severity incidence in two groups were similar, while a much higher mortality was found in COVID-19 patients with cancer compared to that in COVID-19 patients without cancer (11.7% vs. 4.4%, P = 0.028). Furthermore, we found that neutrophil-to-lymphocyte ratio (NLR) and C-reactive protein (CRP) were related to death outcome. And a nomogram based on the factors was developed. CONCLUSION: In COVID-19 patients with cancer, the clinical features and laboratory results between severe group and non-severe group were significantly different. NLR and CRP were the risk factors that could predict death outcome.
BACKGROUND:Coronavirus disease 2019 (COVID-19) has spread around the world. This retrospective study aims to analyze the clinical features of COVID-19patients with cancer and identify death outcome related risk factors. METHODS: From February 10th to April 15th, 2020, 103 COVID-19patients with cancer were enrolled. Difference analyses were performed between severe and non-severe patients. A propensity score matching (PSM) analysis was performed, including 103 COVID-19patients with cancer and 206 matched non-cancerCOVID-19patients. Next, we identified death related risk factors and developed a nomogram for predicting the probability. RESULTS: In 103 COVID-19patients with cancer, the main cancer categories were breast cancer, lung cancer and bladder cancer. Compared to non-severe patients, severe patients had a higher median age, and a higher proportion of smokers, diabetes, heart disease and dyspnea. In addition, most of the laboratory results between two groups were significantly different. PSM analysis found that the proportion of dyspnea was much higher in COVID-19patients with cancer. The severity incidence in two groups were similar, while a much higher mortality was found in COVID-19patients with cancer compared to that in COVID-19patients without cancer (11.7% vs. 4.4%, P = 0.028). Furthermore, we found that neutrophil-to-lymphocyte ratio (NLR) and C-reactive protein (CRP) were related to death outcome. And a nomogram based on the factors was developed. CONCLUSION: In COVID-19patients with cancer, the clinical features and laboratory results between severe group and non-severe group were significantly different. NLR and CRP were the risk factors that could predict death outcome.